Filing Flows › Clene (CLNN) › Guidance & outlook

Clene (CLNN) guidance and outlook

Clene's 10-Q filed Nov 4, 2026 makes 31 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 4, 2026

• Unless the context otherwise requires, for purposes of this section, the terms the “ Company, ” “ we, ” “ us, ” or “ our ” are intended to mean the business and operations of Clene Inc. and its consolidated subsidiaries.
• Our nanotherapeutics target cellular energy impairments that are common to many diseases and we are currently focused on addressing the high unmet medical needs in central nervous system disorders including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”).
• We anticipate this revenue to be small compared to our operating expenses and to the revenue we expect to generate from potential future sales of our drug candidates, for which we are currently conducting clinical trials.
• We expect a response from the FDA before the end of 2026 regarding whether it will accept and review our NDA based on the existing regulatory framework.
• We plan to initiate a Phase 3 RESTORE-ALS trial during the second quarter of 2027, which will serve as the post-approval confirmatory study.
• We plan to work closely with regulatory health authorities from the FDA, European Medicines Agency and other international regulatory bodies, MS experts, and patient representatives to determine the proper path to advance CNM-Au8 into Phase 3 and potential future approval.
• We also believe that once CNM-Au8 receives regulatory approval in another indication, licensing opportunities for the MS indication will improve.
• We anticipate that our research and development expenses will increase in future years if and when we advance our assets into Phase 3.
• Additionally, if the FDA accepts our NDA for review under an accelerated approval pathway or subsequent to future Phase 3 clinical development activities, if any, we anticipate that our research and development expenses related to regulatory activities would increase in advance of receiving regulatory approval.
• We anticipate that our general and administrative expenses in future periods will be contingent upon our regulatory pathway with the FDA.
• If the FDA accepts our NDA for review under an accelerated approval pathway, we anticipate our general and administrative expenses would increase in future periods to support increases in our drug development activities and as we build our commercial capabilities in advance of receiving regulatory approval.
• If the FDA does not accept our NDA for review, or if our NDA is not approved, we would need to continue investing in clinical research activities and we anticipate our general and administrative expenses would decrease in future periods as we decrease commercial manufacturing expansion projects, including at our Elkton, Maryland facility, and as we implement cost-saving initiatives, such as a reduction in…

Clene's latest quarter

Questions

What does Clene expect?

Unless the context otherwise requires, for purposes of this section, the terms the “ Company, ” “ we, ” “ us, ” or “ our ” are intended to mean the business and operations of Clene Inc. and its consolidated subsidiaries. Our nanotherapeutics target cellular energy impairments that are common to many diseases and we are currently focused on addressing the high unmet medical needs in central nervous system disorders including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”). We anticipate this revenue to be small compared to our operating expenses

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.